Report of Positive Results with Innovative Pro-Healing Stent is Featured at
ESC Congress 2007
VIENNA, Austria, Sept. 3 /PRNewswire/ -- OrbusNeich today announced that post-marketing data from patient subsets of a global registry support the use of the company's Genous(TM) Bio-engineered R stent(TM) as an alternative to drug-eluting stents.
Presented today by Robbert de Winter, M.D., Ph.D., at the European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria, the data from OrbusNeich's e-HEALING registry show:
* For 296 diabetic patients at six months, the target lesion
revascularization (TLR) rate was 2%, which is much lower than was
* A TLR rate of 1.9% for 213 chronic total occlusion (CTO) patients at ]
* For 923 patients with statin use, the major adverse cardiac events
(MACE) rate at six months was 5.7%, while 116 patients without statin
use experienced a MACE rate of 6.9% over the same period
"This real-world data strengthen our belief that Genous is a very promising alternative to drug-eluting stents," said de Winter, a co-principal investigator of the study and director of the catheterization laboratory at the Academic Medical Center in Amsterdam. "Genous appears to have the same efficacy as drug-eluting stents but a better safety profile with only minimal dual-antiplatelet therapy requirements. This is an important finding in that physicians are becoming reluctant to burden their patients with the cost and compliance issues associated with drug-eluting stents and their extensive dual-antiplatelet therapy requirements."
OrbusNeich's e-HEALING is a multi-center, worldwide (outside the United
States) prospective registry of patients treated with the Genous Bio-
engineered R stent in accordance with the instructions for use. The
protocol recommends that patients receive two weeks of statin treatment
Copyright©2007 PR Newswire.
All rights reserved